6533b872fe1ef96bd12d42d8

RESEARCH PRODUCT

Exome sequencing in suspected monogenic dyslipidemias.

Sigrid W. FouchierSekar KathiresanSekar KathiresanJames G. WilsonMarjorie RismanBenjamin M. NealeBenjamin M. NealeCatherine BoileauCatherine BoileauMasa-aki KawashiriM. Mahdi MotazackerMathilde VarretJohn J.p. KasteleinDaniel J. RaderG. Kees HovinghClive R. PullingerJorge F. HallerMaurizio AvernaStephen S. RichAngelo B. CefalùIsabelle RuelJacques GenestNathan O. StitzielRahul C. DeoNamrata GuptaDavide NotoDeborah A. NickersonJohn P. KaneHiroshi MabuchiJean-pierre RabèsJean-pierre RabèsStacey GabrielZuhier AwanMason W. FreemanDeborah N. FarlowPatrizia TarugiAtsushi NoharaMark J. DalyMark J. DalyJay ShendureGina M. PelosoGina M. PelosoHayato TadaHayato TadaMasakazu YamagishiMarianne AbifadelMarianne AbifadelDaniel B. Larach

subject

MaleSettore MED/09 - Medicina InternaMedical BiotechnologyDNA sequencing; exome; exome sequencing; genetics human; lipids; mendelian geneticsBiologyCardiorespiratory Medicine and HaematologyNovel genelipidsmendelian geneticsGene mappingClinical ResearchGenetics2.1 Biological and endogenous factorsHumansgeneticsExomeDNA sequencinghumanAetiologyMendelian disordersExomeGenetics (clinical)Exome sequencingDyslipidemiasGeneticsInborn ErrorsHuman GenomeHigh-Throughput Nucleotide SequencingAtherosclerosisMetabolismCardiovascular System & Hematologylipids (amino acids peptides and proteins)DNA sequencing; exome; genetics; human; lipidsFemalegeneticCardiology and Cardiovascular Medicineexome sequencingexomeMetabolism Inborn Errors

description

Background— Exome sequencing is a promising tool for gene mapping in Mendelian disorders. We used this technique in an attempt to identify novel genes underlying monogenic dyslipidemias. Methods and Results— We performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gene sequencing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-density lipoprotein cholesterol. We used standard analytic approaches to identify candidate variants and also assigned a polygenic score to each individual to account for their burden of common genetic variants known to influence lipid levels. In 9 families, we identified likely pathogenic variants in known lipid genes ( ABCA1 , APOB , APOE , LDLR, LIPA , and PCSK9 ); however, we were unable to identify obvious genetic etiologies in the remaining 32 families, despite follow-up analyses. We identified 3 factors that limited novel gene discovery: (1) imperfect sequencing coverage across the exome hid potentially causal variants; (2) large numbers of shared rare alleles within families obfuscated causal variant identification; and (3) individuals from 15% of families carried a significant burden of common lipid-related alleles, suggesting complex inheritance can masquerade as monogenic disease. Conclusions— We identified the genetic basis of disease in 9 of 41 families; however, none of these represented novel gene discoveries. Our results highlight the promise and limitations of exome sequencing as a discovery technique in suspected monogenic dyslipidemias. Considering the confounders identified may inform the design of future exome sequencing studies.

10.1161/circgenetics.114.000776https://pubmed.ncbi.nlm.nih.gov/25901036